CD96

Across TCGA pan-cancer cohorts, CD96 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD96 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CD96 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD96 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, BRCA, and LUAD are the cancer types where CD96 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	III,IV	0.187	0.564	.003	21	view →
BRCA	OS	Median	All	0.117	0.578	.017	12	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	6	view →
BLCA	DFS	Median	II,III,IV	0.915	0.607	.046	4	view →
LGG	OS	Median	All	0.350	0.799	.022	3	view →
UCEC	DFS	Median	All	0.928	0.828	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD96–LUSC (DFS)

Open the LUSC breakdown →